Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 41
2004 55
2005 126
2006 166
2007 224
2008 285
2009 342
2010 375
2011 434
2012 512
2013 520
2014 509
2015 527
2016 574
2017 595
2018 568
2019 264
2020 8
Text availability
Article attribute
Article type
Publication date

Search Results

5,125 results
Results by year
Filters applied: . Clear all
Page 1
SB5: An Adalimumab Biosimilar.
Frampton JE. BioDrugs 2018 - Review. PMID 30251234
The safety and tolerability profile of SB5 was similar to that of reference adalimumab, as was the immunogenicity profile. Switching from reference adalimumab to SB5 had no impact in terms of efficacy, safety or immunogenicity. The role of reference adalimumab in the management of RA, pJIA, ERA, AS, nr-axSpA, PsA, psoriasis, pediatric plaque psoriasis, HS, Crohn's disease, UC and non-infectious uveitis is well established and SB5 provides an effective biosimilar alternative for patients requiring adalimumab therapy....
The safety and tolerability profile of SB5 was similar to that of reference adalimumab, as was the immunogenicity profile. Switching …
Adalimumab for the treatment of uveitis.
LaMattina KC and Goldstein DA. Expert Rev Clin Immunol 2017 - Review. PMID 28140700
Adalimumab, an inhibitor of tumor necrosis factor-alpha (TNFα), is the only systemic non-corticosteroid agent which has been approved by the US Food and Drug Administration (FDA) for the treatment of non-infectious uveitis. Areas covered: The aim of this review is to summarize the research which demonstrated the effectiveness of adalimumab in the treatment of intraocular inflammation and helped to establish its side effect profile, ultimately leading to its FDA approval. ...
Adalimumab, an inhibitor of tumor necrosis factor-alpha (TNFα), is the only systemic non-corticosteroid agent which has been approved
Adalimumab: A Review in Hidradenitis Suppurativa.
Kim ES, et al. Am J Clin Dermatol 2016 - Review. PMID 27665300
This article reviews the clinical efficacy and safety of subcutaneous adalimumab in patients with moderate to severe HS. In clinical trials (PIONEER I and II), a greater proportion of adalimumab than placebo recipients reached HS clinical response (HiSCR) at week 12. ...In addition, adalimumab showed the potential to reduce the high health-related quality of life burden of HS and increase patient satisfaction. ...
This article reviews the clinical efficacy and safety of subcutaneous adalimumab in patients with moderate to severe HS. In clinical …
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K, et al. J Am Acad Dermatol 2017 - Clinical Trial. PMID 28057361 Free article.
OBJECTIVE: We sought to assess efficacy and safety of guselkumab in moderate to severe psoriasis versus placebo and adalimumab, including interrupted treatment and switching adalimumab nonresponders to guselkumab. ...CONCLUSIONS: Guselkumab is a highly effective, well-tolerated, maintenance therapy, including in adalimumab nonresponders....
OBJECTIVE: We sought to assess efficacy and safety of guselkumab in moderate to severe psoriasis versus placebo and adalimumab, inclu …
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A, et al. J Am Acad Dermatol 2017 - Clinical Trial. PMID 28057360 Free article.
BACKGROUND: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. OBJECTIVES: We sought to compare efficacy and safety of guselkumab with adalimumab and placebo in patients with psoriasis treated for 1 year. ...
BACKGROUND: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II …
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R, et al. Lancet 2017 - Clinical Trial. PMID 28629665
FINDINGS: 1146 patients received treatment (384 had tofacitinib monotherapy; 376 had tofacitinib and methotrexate; and 386 had adalimumab and methotrexate). ...Non-inferiority was declared for tofacitinib and methotrexate versus adalimumab and methotrexate (difference 2% [98·34% CI -6 to 11]) but not for tofacitinib monotherapy versus either adalimumab and methotrexate (-6 [-14 to 3]) or tofacitinib and methotrexate (-8 [-16 to 1]). ...
FINDINGS: 1146 patients received treatment (384 had tofacitinib monotherapy; 376 had tofacitinib and methotrexate; and 386 had adalimumab
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, et al. N Engl J Med 2019 - Clinical Trial. PMID 31553834
RESULTS: A total of 769 patients underwent randomization and received at least one dose of vedolizumab (383 patients) or adalimumab (386 patients). ...Corticosteroid-free clinical remission occurred in 12.6% of the patients in the vedolizumab group and in 21.8% in the adalimumab group (difference, -9.3 percentage points; 95% CI, -18.9 to 0.4). ...
RESULTS: A total of 769 patients underwent randomization and received at least one dose of vedolizumab (383 patients) or adalimumab ( …
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Kimball AB, et al. N Engl J Med 2016 - Clinical Trial. PMID 27518661 Free article.
In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor α, showed efficacy against hidradenitis suppurativa. ...In period 1, patients were randomly assigned in a 1:1 ratio to 40 mg of adalimumab weekly or matching placebo for 12 weeks. In period 2, patients were reassigned to adalimumab at a weekly or every-other-week dose or to placebo for 24 weeks. ...
In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor α, showed efficacy against hidradenitis suppurativa. ...In …
Adalimumab in Chronic Plaque Psoriasis: A Clinical Guide.
Wu JJ and Valdecantos WC. J Drugs Dermatol 2017 - Review. PMID 28809993
</p> <p>Here we provide a clinical guide for adalimumab and review existing data on the efficacy and safety of originator adalimumab in moderate-severe chronic plaque psoriasis in adult and pediatric patients. ...Finally, we examine available real-world clinical data for adalimumab in psoriasis.</p> <p><em>J Drugs Dermatol. 2017;16(8):779-790....

Here we provide a clinical guide for adalimumab and review existing data on the efficacy and safety of originator …

GP2017: An Adalimumab Biosimilar.
Heo YA. BioDrugs 2018 - Review. PMID 30460599
GP2017 (adalimumab) is a biosimilar anti-TNF-α antibody. It is approved in the EU for use in all indications for which reference adalimumab is approved. ...The role of reference adalimumab in the management of autoimmune inflammatory conditions is well established and GP2017 provides an effective biosimilar alternative for patients requiring adalimumab therapy....
GP2017 (adalimumab) is a biosimilar anti-TNF-α antibody. It is approved in the EU for use in all indications for which reference a
5,125 results
Jump to page
Feedback